Video content above is prompted by the following:
- (PINKERTON) Sleep has been identified as an independent symptom from hot flashes. With the emerging research regarding the use of elinzanetant to combat sleep disturbances associated with menopause [such as anticipated data from the NIRVANA trial], how important is it to address sleep as part of menopause management, even in the absence of vasomotor symptoms, and how is sleep quality linked to other complications such as mood disorders, cardiovascular disease, and Alzheimer disease?
- What role do you anticipate elinzanetant to have in this space?
- (FIFFICK) How do you anticipate the treatment paradigm of VMS associated with menopause to shift with the advent of these new neurokinin-targeted therapies?
- Please discuss your thoughts on whether they’ll become a new standard of care, and if you anticipate them being used as monotherapy vs combination therapy.
